AutoCRAT

AutoCRAT

Abstract

Osteoarthritis is a common type of arthritis associated with a breakdown of cartilage in joints. It is the most common chronic joint condition, affecting more than 40 million people in Europe alone. As there are limited treatment options available, osteoarthritis imposes a huge burden on healthcare systems. The goal of the EU-funded AutoCRAT project is to develop novel sustainable cell and cell-derived therapies for osteoarthritis. The project will use human-induced pluripotent stem cells for generation of articular chondrocytes for cartilage repair and human-induced mesenchymal stem cells for disease prevention and for the treatment of established disease. As an extended goal, the project will investigate potential application of the mesenchymal stem cell secretome as a next-generation therapy and will produce the therapeutics identified in the project using cost-effective robot-enabled processes in a novel manufacturing platform to expedite translation to patients.

Consortium

NUI Galway (Coordinator), Fraunhofer Gesellschaft Zur Foerderung der Angewandten Forschung EV, Universita Degli Studi di Genova, Academisch Ziekenhuis Leiden, Goeteborgs Universitet, Valitacell LTD, Universitaetsklinikum Essen, Pintail LTD, Panaxea BV

For more information visit AutoCRAT